Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Go or no go? Novartis, Sanofi and Regeneron await US verdicts
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
AACR 2019 – Chi-Med has savolitinib filing in its sights
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Go or no go? Sanofi’s Cablivi leads February’s approvals charge
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Christmas comes early for Agenus
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
SITC 2018 – Nektar’s big reveal falls flat
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
SITC event – Nektar hopes to pivot away from Incyte's failure
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.